NEW YORK – Investment firm UBS said on Monday that it is downgrading Illumina's stock from a 'buy' to a 'neutral' rating, following Illumina's announcement that it plans to acquire cancer diagnostics firm Grail for $8 billion in cash and stock.
UBS also lowered its price target for Illumina's stock to $285 from $390 per share.